Shea Edwards
Payments from drug & device makers
Across 323 payments — averaging $14.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$803
- GSK$513
- Amgen$405
- Lilly USA, LLC$341
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$340
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,804100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 90 | $1,166 |
| Novo Nordisk | 55 | $803 |
| GSK | 35 | $513 |
| Amgen | 24 | $405 |
| Lilly USA, LLC | 23 | $341 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $340 |
| Amarin Pharma, Inc. | 11 | $227 |
| Johnson & Johnson | 9 | $148 |
| Esperion Therapeutics, Inc. | 7 | $104 |
| Exact Sciences | 5 | $88 |
| Tris Pharma Inc | 5 | $84 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $84 |
| AstraZeneca | 5 | $80 |
| Bayer | 4 | $72 |
| Organon | 3 | $49 |
| Lundbeck LLC | 3 | $49 |
| Renalytix AI, Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Dexcom, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Alkermes, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Pfizer | 1 | $18 |
| Global Blood Therapeutics, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$4,804 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 48 | $49,355 |
| JardianceEmpagliflozin | 68 | $42,172 |
| EliquisApixaban | 43 | $30,242 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $22,908 |
| TrulicityDulaglutide | 24 | $22,452 |
| JanuviaSitagliptin Phosphate | 14 | $8,704 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $8,451 |
| NexletolBempedoic Acid | 14 | $6,279 |
| BelsomraSuvorexant | 13 | $5,235 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $1,596 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $1,312 |
| Gabapentin | 76 | $890 |
| Ezetimibe | 56 | $882 |
| Levothyroxine Sodium | 74 | $754 |
| SynthroidLevothyroxine Sodium | 13 | $749 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $341 | $71,80772 claims |
| Boehringer IngelheimJardiance | $14 | $42,17268 claims |
| PfizerEliquis | $18 | $30,24243 claims |
| GSKTrelegy Ellipta | $513 | $22,90832 claims |
| Esperion Therapeutics, Inc.Nexletol | $104 | $6,27914 claims |
| AbbVieSynthroid | $1,166 | $74913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.
Other family in Amite
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.